BGJ398 in Combination With Imatinib Mesylate in Patients With Untreated Advanced Gastrointestinal Stromal Tumor (GIST)

• ClinicalTrials.gov Identifier: NCT02257541
• Recruitment Status: Completed
• First Posted: October 6, 2014
• Results First Posted: March 30, 2020
• Last Update Posted: March 30, 2020
• Sponsor: Memorial Sloan Kettering Cancer Center
• Collaborators: Dana-Farber Cancer Institute; M.D. Anderson Cancer Center; University of Pittsburgh
• Information provided by (Responsible Party): Memorial Sloan Kettering Cancer Center

Study Description

Brief Summary:

The goal of a phase Ib clinical trial is to find the doses of drugs that are safe. Although BGJ398 has been given to patients safely on its own, it has never been given together with imatinib mesylate. In this study, we will test the safety of taking BGJ398 with imatinib mesylate. The investigators will learn this by closely checking for side effects that the patient may experience. Side effects can be seen in laboratory studies, on physical examination, or by asking the patient.Once a dose has been determined to be safe, a larger Phase II study will be done in patients with advanced GIST who have never received any prior treatments.

Condition or disease	Intervention/treatment	Phase
Advanced Gastrointestinal Stromal Tumor (GIST)	Drug: BGJ398; Drug: Imatinib Mesylate	Phase 1; Phase 2

Study Design

• Study Type: Interventional (Clinical Trial)
• Actual Enrollment: 16 participants
• Allocation: N/A
• Intervention Model: Single Group Assignment
• Masking: None (Open Label)
• Primary Purpose: Treatment
• Official Title: A Phase Ib/II Study of BGJ398 in Combination With Imatinib Mesylate in Patients With Untreated Advanced Gastrointestinal Stromal Tumor (GIST)
• Actual Study Start Date: October 2, 2014
• Actual Primary Completion Date: March 25, 2019
• Actual Study Completion Date: March 25, 2019

Arms and Interventions

Arm

Intervention/treatment

Experimental: BGJ398 With Imatinib Mesylate; BGJ398 With Imatinib Mesylate In the phase Ib portion of the study, patients will receive imatinib at 400 mg once daily and BGJ398 at the standard 3+3 escalation doses for 21 days on, 7 days off (treatment schedule A).Using treatment schedule A, if dose level 1 to -2 is identified as the MTD and concern exists regarding therapeutic activity of BGJ398 at this dose level, expansions with higher dose levels (1 to 3) may be considered at the MSKCC PI's discretion, with modification of the treatment schedule. In this setting BGJ398 will be administered daily for one week followed by 3 weeks off and imatinib will be taken daily throughout the 4 week cycle period (treatment schedule B). In the phase II portion of the study, patients will receive imatinib at 400 mg once daily (standard of care first line imatinib dose) and BGJ398 at the RP2D and treatment schedule identified in the phase Ib portion of the study. One cycle is 28 days.

Drug: BGJ398; Drug: Imatinib Mesylate

Outcome Measures

Primary Outcome Measures :

1. Phase Ib Study: Number of Participants With Dose-Limiting Toxicities [ Time Frame: 1 year ]
   The phase Ib will be pursued in standard 3+3 format, based on toxicities encountered during the first cycle of therapy.
2. Phase Ib Portion: Response Rate (RR) [ Time Frame: 32 weeks ]

   (CR+PR, RECIST 1.1) and by CHOI criteria

   PHASE 1b PARTICIPANTS ONLY

   Per Response Evaluation Criteria In Solid Tumors Criteria (RECIST v1.0) for target lesions and assessed by MRI: Complete Response (CR), Disappearance of all target lesions; Partial Response (PR), >=30% decrease in the sum of the longest diameter of target lesions; Overall Response (OR) = CR + PR

Secondary Outcome Measures :

1. Phase Ib Study: Response Rate (RR) [ Time Frame: 32 weeks ]

   defined by RECIST 1.1 criteria and by CHOI criteria,and by EORTC criteria

   PHASE 1b PARTICIPANTS ONLY

   Per Response Evaluation Criteria In Solid Tumors Criteria (RECIST v1.0) for target lesions and assessed by MRI: Complete Response (CR), Disappearance of all target lesions; Partial Response (PR), >=30% decrease in the sum of the longest diameter of target lesions; Overall Response (OR) = CR + PR

Eligibility Criteria

• Ages Eligible for Study: 18 Years and older (Adult, Older Adult)
• Sexes Eligible for Study: All
• Accepts Healthy Volunteers: No

Criteria

Inclusion Criteria:

• Patients must have pathologically confirmed GIST.
• In the Phase Ib portion, must have locally advanced or metastatic GIST and have progressed on imatinib.
• In the Phase II portion, patients must be newly diagnosed or imatinib treatment naïve in the advanced/metastatic setting. Prior adjuvant imatinib therapy is allowed as long as disease recurrence was documented ≥90 days after last dose of imatinib and imatinib has not yet been restarted.
• Patients must be at least 18 years of age.
• Disease must be measurable by RECIST 1.1.
• ECOG Performance Status 0 or 1. Adequate renal, hepatic, and hematologic function as the following: Serum Creatinine ≤ 1.5 mg/dL, Total Serum Bilirubin ≤ 1.5 x upper limit of normal (ULN) unless due to Gilbert's Disease, Serum AST (SGOT) and/or ALT (SGPT) ≤ 2.5 x ULN (or ≤ 5.0 x ULN if considered due to tumor), ANC ≥ 1500/mm3, Platelets ≥ 100,000/mm3, and hemoglobin ≥ 10g/dL.
• Patients of childbearing potential must have a negative blood pregnancy test within 14 days of treatment. Patients must agree to use a reliable barrier method of birth control during and for 3 months following the last dose of study drug.
• Patient must have adequate cardiac function (left ventricular ejection fraction (LVEF) ≥50% as determined by a multigated acquisition (MUGA) scan or echocardiogram; and QTc interval ≤480 ms by Fridericia's formula (QTcF).
• Patient must be able to take oral medications.
• Patients must sign an informed consent document.

Exclusion Criteria:

• For phase I, prior intolerance to imatinib at a dose of 400 mg daily.
• For phase II, any receipt of cytotoxic, biologic, or immune therapy aimed to treat GIST except for adjuvant imatinib systemic therapy that concluded at least 90 days prior to registration. For Phase I, patients are eligible regardless of prior therapy.
• Chronic liver disease (e.g., cirrhosis)
• Known positive serology for HIV, active Hepatitis B, and/or active Hepatitis C infection.
• Patients have a history or current evidence of Central Serous Retinopathy (CSR) or retinal vein occlusion (RVO) or major predisposing factors to CSR or RVO (e.g. uncontrolled glaucoma or ocular hypertension) in the opinion of the study ophthalmologist.
• History of retinal degenerative disease
• Active corneal disorder or keratopathy (e.g. corneal abrasion, bullous keratopathy)

• Severe and/or uncontrolled medical disease, including:

  • Uncontrolled diabetes mellitus (A1c >8)
  • Chronic Kidney Disease Stage III or higher (Creatinine Clearance <60mL/min/m2 by Modified Diet in Renal Disease (MDRD) calculation)
  • Active, uncontrolled infection Known active brain metastasis unless they have been treated and shown documented radiographic stability for 28 days.
• Known other active malignancy (other than malignancies which the investigator determines are unlikely to interfere with treatment and safety analysis).

• Patients have clinically significant cardiovascular disease, including any of the following

  • Any history of acute coronary syndrome including myocardial infarction, stable or unstable angina, CABG, coronary angioplasty or stenting or known obstructive coronary artery disease.
  • Symptomatic chronic heart failure (New York Heart Association Criteria, Class II-IV)
  • Evidence of clinically significant cardiac arrhythmias and/or conduction abnormalities < 6 months prior to screening except atrial fibrillation (AF) and paroxysmal supraventricular tachycardia (PSVT)
• Any history of thrombotic cerebrovascular accident or other arterial thrombosis
• Uncontrolled arterial hypertension (systolic blood pressure >155 mmHg or diastolic >95 mmHg) despite appropriate medical therapy.
• History and/or current evidence of uncontrolled endocrine alterations of calcium/phosphate homeostasis, e.g., parathyroid disorders, history of parathyroidectomy, tumor lysis, tumoral calcinosis, etc.
• Impairment of gastrointestinal function or gastrointestinal disease (e.g., uncontrolled ulcerative disease; uncontrolled nausea, vomiting, diarrhea; chronic malabsorption syndrome).
• Patients with major surgery within 3 weeks prior to study entry or who have not recovered from side effects of such procedure.
• Women who are pregnant or lactating.
• Sexually active males, unless they use a condom during intercourse while taking the drug and for 15 days after stopping treatment. They should not father a child in this period. A condom is required to be used also by vasectomized men in order to prevent delivery of the drug via seminal fluid.
• Patients with any significant history of non-adherence to medical regimens or with inability to grant reliable informed consent.

Contacts and Locations

Locations

United States, Massachusetts

Dana Farber Cancer Institute

Boston, Massachusetts, United States, 02115

United States, New Jersey

Memoral Sloan Kettering Cancer Center

Basking Ridge, New Jersey, United States

United States, New York

Memorial Sloan Kettering Cancer Center @ Suffolk

Commack, New York, United States, 11725

Memorial Sloan Kettering Westchester

Harrison, New York, United States, 10604

Memorial Sloan Kettering Cancer Center

New York, New York, United States, 10065

Memorial Sloan Kettering at Mercy Medical Center

Rockville Centre, New York, United States

United States, Texas

Md Anderson Cancer Center

Houston, Texas, United States, 77030

Sponsors and Collaborators

Memorial Sloan Kettering Cancer Center

Dana-Farber Cancer Institute

M.D. Anderson Cancer Center

University of Pittsburgh

Investigators

• Principal Investigator: William Tap, MD; Memorial Sloan Kettering Cancer Center

  Study Documents (Full-Text)

Documents provided by Memorial Sloan Kettering Cancer Center:

Study Protocol and Statistical Analysis Plan  [PDF] January 24, 2017

More Information

Additional Information:

Memorial Sloan Kettering Cancer Center 

Publications automatically indexed to this study by ClinicalTrials.gov Identifier (NCT Number):

Kelly CM, Shoushtari AN, Qin LX, D'Angelo SP, Dickson MA, Gounder MM, Keohan ML, Mcfadyen C, Sjoberg A, Singer S, DeMatteo RP, Hwang S, Heinemann MH, Francis JH, Antonescu CR, Chi P, Tap WD. A phase Ib study of BGJ398, a pan-FGFR kinase inhibitor in combination with imatinib in patients with advanced gastrointestinal stromal tumor. Invest New Drugs. 2019 Apr;37(2):282-290. doi: 10.1007/s10637-018-0648-z. Epub 2018 Aug 13.

• Responsible Party: Memorial Sloan Kettering Cancer Center
• ClinicalTrials.gov Identifier: NCT02257541
• Other Study ID Numbers: 14-140
• First Posted: October 6, 2014
• Results First Posted: March 30, 2020
• Last Update Posted: March 30, 2020
• Last Verified: March 2019

Keywords provided by Memorial Sloan Kettering Cancer Center:

BGJ398; Imatinib Mesylate; 14-140

Additional relevant MeSH terms:

Gastrointestinal Stromal Tumors; Neoplasms, Connective Tissue; Neoplasms, Connective and Soft Tissue; Neoplasms by Histologic Type; Neoplasms; Gastrointestinal Neoplasms; Digestive System Neoplasms; Digestive System Diseases; Gastrointestinal Diseases; Imatinib Mesylate; Antineoplastic Agents; Protein Kinase Inhibitors; Enzyme Inhibitors; Molecular Mechanisms of Pharmacological Action